Whole-Exome Sequencing Reveals Mutational Signature of Hypertrophic Cardiomyopathy

References

• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–770. doi:10.1161/CIRCRESAHA.117.311059
   PubMed Web of Science ®Google Scholar
• McKenna WJ, Sen-Chowdhry S. From Teare to the present day: a fifty year odyssey in hypertrophic cardiomyopathy, a paradigm for the logic of the discovery process. Rev Esp Cardiol. 2008;61:1239–1244. doi:10.1016/S0300-8932(08)75730-0
   PubMed Web of Science ®Google Scholar
• Kuusisto J. Genetics of hypertrophic cardiomyopathy: what is the next step? Heart. 2020;106:1291–1292. doi:10.1136/heartjnl-2020-317043
   PubMed Web of Science ®Google Scholar
• Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242–255. doi:10.1016/S0140-6736(12)60397-3
   PubMed Web of Science ®Google Scholar
• Ušaj M, Moretto L, Månsson A. Critical evaluation of current hypotheses for the pathogenesis of hypertrophic cardiomyopathy. Int J Mol Sci. 2022;23(4):2195. doi:10.3390/ijms23042195
   PubMed Web of Science ®Google Scholar
• Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail. 2018;6:376–378. doi:10.1016/j.jchf.2018.03.004
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124:2761–2796. doi:10.1161/CIR.0b013e318223e230
   PubMed Web of Science ®Google Scholar
• Marsiglia JD, Pereira AC. Hypertrophic cardiomyopathy: how do mutations lead to disease? Arq Bras Cardiol. 2014;102:295–304. doi:10.5935/abc.20140022
   PubMed Web of Science ®Google Scholar
• Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol. 2018;107:30–41. doi:10.1007/s00392-017-1155-5
   PubMed Web of Science ®Google Scholar
• Schuldt M, Pei J, Harakalova M, et al. Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy. Circ Heart Fail. 2021;14:e007022. doi:10.1161/CIRCHEARTFAILURE.120.007022
   PubMed Web of Science ®Google Scholar
• Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014;59:5–15. doi:10.1038/jhg.2013.114
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44:760–764. doi:10.1038/ng.2291
   PubMed Web of Science ®Google Scholar
• Ploski R, Pollak A, Müller S, et al. Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy? Circ Res. 2014;114:e2–5. doi:10.1161/CIRCRESAHA.114.302662
   PubMed Web of Science ®Google Scholar
• Dubourg O, Isnard R, Hagège A, et al. Doppler echocardiography in familial hypertrophic cardiomyopathy: the French Cooperative Study. Echocardiography. 1995;12:235–241. doi:10.1111/j.1540-8175.1995.tb00544.x
   PubMed Web of Science ®Google Scholar
• Seeger T, Shrestha R, Lam CK, et al. A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation. 2019;139:799–811. doi:10.1161/CIRCULATIONAHA.118.034624
   PubMed Web of Science ®Google Scholar
• Robert-Paganin J, Auguin D, Houdusse A. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition. Nat Commun. 2018;9:4019. doi:10.1038/s41467-018-06191-4
   PubMed Web of Science ®Google Scholar
• Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:436–441. doi:10.1161/CIRCGENETICS.108.821314
   PubMedGoogle Scholar
• Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727–737. doi:10.1016/j.mayocp.2014.01.025
   PubMed Web of Science ®Google Scholar
• Mogensen J, Hey T, Lambrecht S. A systematic review of phenotypic features associated with cardiac troponin I mutations in hereditary cardiomyopathies. Can J Cardiol. 2015;31:1377–1385. doi:10.1016/j.cjca.2015.06.015
   PubMed Web of Science ®Google Scholar
• Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:2315–2325. doi:10.1016/j.jacc.2004.05.088
   PubMed Web of Science ®Google Scholar
• Mak TSH, Lee YK, Tang CS. Coverage and diagnostic yield of whole exome sequencing for the evaluation of cases with dilated and hypertrophic cardiomyopathy. Sci Rep. 2018;8:10846. doi:10.1038/s41598-018-29263-3
   PubMed Web of Science ®Google Scholar
• Ruan L, Yang Y, Huang Y, Ding L, Zhang C, Wu X. Functional prediction of miR-3144-5p in human cardiac myocytes based on transcriptome sequencing and bioinformatics. Medicine. 2017;96(32):e7539. doi:10.1097/MD.0000000000007539
   PubMed Web of Science ®Google Scholar
• Zhou Y, Qian Z, Yang J, et al. Whole exome sequencing identifies novel candidate mutations in a Chinese family with left ventricular noncompaction. Mol Med Rep. 2018;17:7325–7330. doi:10.3892/mmr.2018.8777
   PubMed Web of Science ®Google Scholar
• Masuda S, Matsuura K, Shimizu T. Inhibition of LYPD1 is critical for endothelial network formation in bioengineered tissue with human cardiac fibroblasts. Biomaterials. 2018;166:109–121. doi:10.1016/j.biomaterials.2018.03.002
   PubMed Web of Science ®Google Scholar
• Angrisano T, Schiattarella GG, Keller S, et al. Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure. PLoS One. 2014;9:e106024. doi:10.1371/journal.pone.0106024
   PubMed Web of Science ®Google Scholar
• Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8. doi:10.1136/hrt.20.1.1
   PubMedGoogle Scholar
• Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA. 2015;112:5473–5478. doi:10.1073/pnas.1418631112
   PubMed Web of Science ®Google Scholar
• Yu W, Huang MM, Zhang GH, Wang W, Chen CJ, Cheng JD. Whole-exome sequencing reveals MYH7 p.R671C mutation in three different phenotypes of familial hypertrophic cardiomyopathy. Exp Ther Med. 2021;22:1002. doi:10.3892/etm.2021.10434
   PubMed Web of Science ®Google Scholar
• Millat G, Bouvagnet P, Chevalier P, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53:261–267. doi:10.1016/j.ejmg.2010.07.007
   PubMed Web of Science ®Google Scholar
• Lombardi M, Lazzeroni D, Pisano A, et al. Mitochondrial energetics and Ca2(+)-activated ATPase in obstructive hypertrophic cardiomyopathy. J Clin Med. 2020;9:1799. doi:10.3390/jcm9061799
   PubMed Web of Science ®Google Scholar